Signal Seven psychedelic candidates have reached FDA Phase 3 trials

Summary

GWI's Psychedelics and Healing Initiative lists seven psychedelic candidate drugs that have reached FDA Phase 3, the final stage before consideration for approval. The named indications cover treatment-resistant depression, major depressive disorder, generalized anxiety disorder, post-traumatic stress disorder and severe alcohol use disorder, across compounds from six separate developers.